Interested in Connecting? Please contact:
Elliot Fisher
CBO
elliot@curibio.com

Message the company or request a 1:1 meeting here

Curi Bio’s discovery engine combines human stem cells, systems, and data to accelerate the discovery of new medicines. Curi Bio has developed a comprehensive preclinical platform—the Curi Engine—integrating human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.

Pitch Video